Evidence map›Paper›PMID 25887091›Full record

ArticleBMC microbiology2015

Rhodococcus erythropolis MTHt3 biotransforms ergopeptines to lysergic acid.

Michaela Thamhesl, Elisabeth Apfelthaler, Heidi Elisabeth Schwartz-Zimmermann, Elisavet Kunz-Vekiru, Rudolf Krska, Wolfgang Kneifel, Gerd Schatzmayr, Wulf-Dieter Moll

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Microorganisms · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michaela ThamheslBIOMIN Research Center, Technopark 1, 3430, Tulln, Austria. michaela.thamhesl@biomin.net.
Elisabeth ApfelthalerDepartment for Agrobiotechnology (IFA-Tulln), Christian Doppler Laboratory for Mycotoxin Research, Center for Analytical Chemistry, University of Natural Resources and Life Sciences (BOKU) Vienna, Konrad Lorenz Straße 20, 3430, Tulln, Austria. elisabeth.apfelthaler@gmx.at.
Heidi Elisabeth Schwartz-ZimmermannDepartment for Agrobiotechnology (IFA-Tulln), Christian Doppler Laboratory for Mycotoxin Research, Center for Analytical Chemistry, University of Natural Resources and Life Sciences (BOKU) Vienna, Konrad Lorenz Straße 20, 3430, Tulln, Austria. heidi.schwartz@boku.ac.at.
Elisavet Kunz-VekiruDepartment for Agrobiotechnology (IFA-Tulln), Christian Doppler Laboratory for Mycotoxin Research, Center for Analytical Chemistry, University of Natural Resources and Life Sciences (BOKU) Vienna, Konrad Lorenz Straße 20, 3430, Tulln, Austria. elisavet.vekiru@boku.ac.at.
Rudolf KrskaDepartment for Agrobiotechnology (IFA-Tulln), Christian Doppler Laboratory for Mycotoxin Research, Center for Analytical Chemistry, University of Natural Resources and Life Sciences (BOKU) Vienna, Konrad Lorenz Straße 20, 3430, Tulln, Austria. rudolf.krska@boku.ac.at.
Wolfgang KneifelChristian Doppler Laboratory for Innovative Bran Biorefinery, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria. wolfgang.kneifel@boku.ac.at.
Gerd SchatzmayrBIOMIN Research Center, Technopark 1, 3430, Tulln, Austria. gerd.schatzmayr@biomin.net.
Wulf-Dieter MollBIOMIN Research Center, Technopark 1, 3430, Tulln, Austria. dieter.moll@biomin.net.
BOKU University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErgopeptines are a predominant class of ergot alkaloids produced by tall fescue grass endophyte Neotyphodium coenophialum or cereal pathogen Claviceps purpurea. The vasoconstrictive activity of ergopeptines makes them toxic for mammals, and they can be a problem in animal husbandry.

resultsWe isolated an ergopeptine degrading bacterial strain, MTHt3, and classified it, based on its 16S rDNA sequence, as a strain of Rhodococcus erythropolis (Nocardiaceae, Actinobacteria). For strain isolation, mixed microbial cultures were obtained from artificially ergot alkaloid-enriched soil, and provided with the ergopeptine ergotamine in mineral medium for enrichment. Individual colonies derived from such mixed cultures were screened for ergotamine degradation by high performance liquid chromatography and fluorescence detection. R. erythropolis MTHt3 converted ergotamine to ergine (lysergic acid amide) and further to lysergic acid, which accumulated as an end product. No other tested R. erythropolis strain degraded ergotamine. R. erythropolis MTHt3 degraded all ergopeptines found in an ergot extract, namely ergotamine, ergovaline, ergocristine, ergocryptine, ergocornine, and ergosine, but the simpler lysergic acid derivatives agroclavine, chanoclavine, and ergometrine were not degraded. Temperature and pH dependence of ergotamine and ergine bioconversion activity was different for the two reactions.

conclusionsDegradation of ergopeptines to ergine is a previously unknown microbial reaction. The reaction end product, lysergic acid, has no or much lower vasoconstrictive activity than ergopeptines. If the genes encoding enzymes for ergopeptine catabolism can be cloned and expressed in recombinant hosts, application of ergopeptine and ergine degrading enzymes for reduction of toxicity of ergot alkaloid-contaminated animal feed may be feasible.

Indexed as

AnimalsBiotransformationClavicepsCluster AnalysisDNA, BacterialDNA, RibosomalEpichloeErgot AlkaloidsLysergic AcidMammalsMolecular Sequence DataPhylogenyRhodococcusRNA, Ribosomal, 16SSequence Analysis, DNADNA, BacterialDNA, RibosomalErgot AlkaloidsLysergic AcidRNA, Ribosomal, 16S

Identifiers

PMID25887091
PMCPMC4411749
OpenAlexW2090240611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.